| 1 |
Chen P, Liu Y, Wen Y, et al. Non-small cell lung cancer in China[J]. Cancer Commun (Lond), 2022, 42(10): 937-970.
|
| 2 |
Mithoowani H, Febbraro M. Non-small-cell lung cancer in 2022: A review for general practitioners in oncology[J]. Curr Oncol, 2022, 29(3): 1828-1839.
|
| 3 |
Ettinger DS, Wood DE, Aisner DL, et al. Non-small cell lung cancer，version 3.2022, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2022, 20(5): 497-530.
|
| 4 |
Jasper K, Stiles B, McDonald F, et al. Practical management of oligometastatic non-small-cell lung cancer[J]. J Clin Oncol, 2022, 40(6): 635-641.
|
| 5 |
Chang YS, Tu SJ, Chen YC, et al. Mutation profile of non-small cell lung cancer revealed by next generation sequencing[J]. Respir Res, 2021, 22(1): 3.
|
| 6 |
Neumann JM, Freitag H, Hartmann JS, et al. Subtyping non-small cell lung cancer by histology-guided spatial metabolomics[J]. J Cancer Res Clin Oncol, 2022，148(2): 351-360.
|
| 7 |
Dantoing E, Piton N, Salaun M, et al. Anti-PD1/PD-L1 immunotherapy for non-small cell lung cancer with actionable oncogenic driver mutations[J]. Int J Mol Sci, 2021, 22(12): 6288.
|
| 8 |
Higgins KA, Puri S, Gray JE. Systemic and radiation therapy approaches for locally advanced non-small-cell lung cancer[J]. J Clin Oncol, 2022, 40(6): 576-585.
|
| 9 |
Tang A, Ahmad U, Toth AJ, et al. Non-small cell lung cancer in never- and ever-smokers: Is it the same disease？[J]. J Thorac Cardiovasc Surg, 2021, 161(6): 1903-1917.
|
| 10 |
耿海静，王海生，张建宇，等. 人肝癌耐药细胞中差异表达微小RNA的筛选及生物学功能分析[J]. 山东医药，2023, 63(2): 11-15.
|
| 11 |
郝润梅，刘 竟，刘 洁，等. 长链非编码RNA X染色体失活特异转录物和微小RNA-146-5p在甲状腺癌中的表达及临床意义[J]. 实用临床医药杂志，2023, 27(5): 72-75，81.
|
| 12 |
张 羽，张 璨，章伟玲. 长链非编码RNA NR2F1-AS1靶向微小RNA-493-5p表达调控卵巢癌细胞增殖及凋亡的机制研究[J]. 实用临床医药杂志，2023, 27(4): 30-34.
|
| 13 |
周绮纯，王 晰，邓芷茵，等. 微小RNA hsa-miR-93靶向STAT3提高鼻咽癌对放疗敏感性的机制研究[J]. 实用肿瘤学杂志，2023, 37(1): 17-25.
|
| 14 |
李明明，董 辉，李晓燕，等. 尿液miRNA膀胱癌肿瘤标记物筛选和诊断价值分析[J]. 中华肿瘤防治杂志，2020, 27(12): 998-1002，1007.
|
| 15 |
Liu C, Wu W, Chang W, et al. miR-31-5p-DMD axis as a novel biomarker for predicting the development and prognosis of sporadic early-onset colorectal cancer[J]. Oncol Lett, 2022, 23(5): 157.
|
| 16 |
中华医学会病理学分会，国家病理质控中心，中华医学会肿瘤学分会肺癌学组，等. 非小细胞肺癌分子病理检测临床实践指南(2021版)[J]. 中华病理学杂志，2021, 50(4): 323-332.
|
| 17 |
李咏生，孙建国，李梦侠，等. 第三代EGFR-TKI耐药后诊疗策略专家共识[J/CD]. 中华肺部疾病杂志(电子版), 2023, 16(2): 145-155.
|
| 18 |
朱正飞. GEMSTONE-301：同步/序贯放化疗后舒格利单抗巩固治疗可提高不可手术的Ⅲ期非小细胞肺癌患者的生存[J]. 循证医学，2022, 22(1): 4-7.
|
| 19 |
Salgia R, Pharaon R, Mambetsariev I, et al. The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC)[J]. Cell Rep Med, 2021, 2(1): 100186.
|
| 20 |
徐 瑜，白 莉. 广泛期小细胞肺癌免疫治疗新理念[J/CD]. 中华肺部疾病杂志(电子版), 2021, 14(4): 407-411.
|
| 21 |
Mi B, Li Q, Li T, et al. High miR-31-5p expression promotes colon adenocarcinoma progression by targeting TNS1[J]. Aging (Albany NY), 2020, 12(8): 7480-7490.
|
| 22 |
武 伦，汤志刚，李生伟，等. 外泌体miRNA在肿瘤进展中的作用及其可能机制[J]. 中华肝脏病杂志，2021, 29(9): 908-912.
|
| 23 |
吴亚婷，李卓林，雷 艳，等. 尿液中miRNA作为常见恶性肿瘤生物标志物研究进展[J]. 检验医学，2023, 38(1): 94-99.
|
| 24 |
Zhu C, Wang S, Zheng M, et al. miR-31-5p modulates cell progression in lung adenocarcinoma through TNS1/p53 axis[J]. Strahlenther Onkol, 2022, 198(3): 304-314.
|
| 25 |
彭 洪，彭明沙，冯雪雅，等. 环状RNA circ0000601通过miR-31-5p调控NUMB抑制结直肠癌细胞增殖[J]. 中华内分泌外科杂志，2019, 13(5): 429-434.
|
| 26 |
胡先华，赵春艳，张海迪，等. 2-脱氧-D-葡萄糖通过诱导人非小细胞肺癌细胞线粒体功能障碍抑制肿瘤细胞增殖[J]. 中国免疫学杂志，2021, 37(7): 829-833.
|
| 27 |
Cheng X, Sha M, Jiang W, et al. LINC00174 suppresses non-small cell lung cancer progression by up-regulating LATS2 via sponging miR-31-5p[J]. Cell J, 2022, 24(3): 140-147.
|
| 28 |
赖庆君，李丽萍，张曼曼，等. 非小细胞肺癌组织中微小RNA-15b的表达及其与免疫功能和预后的关系[J]. 中国医刊，2022, 57(4): 437-441.
|